Dutch startup Kynexis is developing a novel treatment for cognitive impairment associated with schizophrenia (CIAS), a condition that affects over 24 million individuals globally and can be a major source of disability. Their approach is based on understanding human biology, pinpointing the exact cause of the condition using biomarkers, and identifying specific groups of individuals who respond well to the treatment based on genetic factors. Kynexis is taking a precise approach by targeting a crucial enzyme called KAT-II in the kynurenine pathway. They have developed a small molecule called KYN-5356, which is potentially highly effective at inhibiting KAT-II, addressing challenges that previous attempts to target this enzyme have faced. KYN-5356 was in preclinical stages as of November 2023.
Funding and financials
In November 2023, the company was launched with USD 61 million in Series A funding led by Forbion. The funds are earmarked for advancing KYN-5356 toward clinical development, with the company aiming to fulfill the urgent need for effective treatments for cognitive impairments in schizophrenia
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.